These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 32776218

  • 21. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.
    Cancer; 2015 Feb 01; 121(3):372-8. PubMed ID: 25236687
    [Abstract] [Full Text] [Related]

  • 22. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    Cao WM, Gao Y, Yang HJ, Xie SN, Ding XW, Pan ZW, Ye WW, Wang XJ.
    BMC Cancer; 2016 Feb 06; 16():64. PubMed ID: 26852015
    [Abstract] [Full Text] [Related]

  • 23. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.
    Ann Oncol; 2011 Apr 06; 22(4):964-966. PubMed ID: 20924075
    [Abstract] [Full Text] [Related]

  • 24. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.
    Neoplasma; 2006 Apr 06; 53(2):97-102. PubMed ID: 16575464
    [Abstract] [Full Text] [Related]

  • 25. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoori AR, Seidel-Renkert A, Farooq H, Narod S, Amin A, Hamann U.
    Int J Cancer; 2006 Dec 15; 119(12):2832-9. PubMed ID: 16998791
    [Abstract] [Full Text] [Related]

  • 26. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
    Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV, Zaitseva OA, Yatsuk OS, Togo AV, Tkachenko NN, Shiyanov GA, Lobeiko OS, Krylova NY, Matsko DE, Maximov SY, Urmancheyeva AF, Porhanova NV, Imyanitov EN.
    Hered Cancer Clin Pract; 2009 Feb 25; 7(1):5. PubMed ID: 19338682
    [Abstract] [Full Text] [Related]

  • 27. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A, German Consortium for Hereditary Breast and Ovarian Cancer.
    Int J Cancer; 2002 Feb 01; 97(4):472-80. PubMed ID: 11802209
    [Abstract] [Full Text] [Related]

  • 28. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 01; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 29. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
    Rybchenko LA, Poluben LO, Bychkova GM, Stephanovych GV, Klymenko SV.
    Probl Radiac Med Radiobiol; 2019 Dec 01; 24():455-464. PubMed ID: 31841487
    [Abstract] [Full Text] [Related]

  • 30. Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
    Pinto P, Peixoto A, Santos C, Rocha P, Pinto C, Pinheiro M, Leça L, Martins AT, Ferreira V, Bartosch C, Teixeira MR.
    PLoS One; 2016 Dec 01; 11(8):e0161438. PubMed ID: 27532258
    [Abstract] [Full Text] [Related]

  • 31. BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
    Ławniczak M, Jakubowska A, Białek A, Lubiński J, Jaworska-Bieniek K, Kaczmarek K, Starzyńska T.
    Hered Cancer Clin Pract; 2016 Dec 01; 14():3. PubMed ID: 26779294
    [Abstract] [Full Text] [Related]

  • 32. Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.
    Elalaoui SC, Laarabi FZ, Afif L, Lyahyai J, Ratbi I, Jaouad IC, Doubaj Y, Sahli M, Ouhenach M, Sefiani A.
    Breast Cancer Res Treat; 2022 Jul 01; 194(1):187-198. PubMed ID: 35578052
    [Abstract] [Full Text] [Related]

  • 33. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.
    Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES.
    PLoS One; 2012 Jul 01; 7(9):e43994. PubMed ID: 22970155
    [Abstract] [Full Text] [Related]

  • 34. A high proportion of founder BRCA1 mutations in Polish breast cancer families.
    Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Tołoczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojć B, Mierzejewski M, Narod SA, Lubiński J.
    Int J Cancer; 2004 Jul 10; 110(5):683-6. PubMed ID: 15146557
    [Abstract] [Full Text] [Related]

  • 35. Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.
    Kaduri L, Gibs M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D, Peretz T.
    Eur J Obstet Gynecol Reprod Biol; 1999 Jul 10; 85(1):75-80. PubMed ID: 10428326
    [Abstract] [Full Text] [Related]

  • 36. Genetic Analysis of Multiple Primary Malignant Tumors in Women with Breast and Ovarian Cancer.
    Savkova A, Gulyaeva L, Gerasimov A, Krasil'nikov S.
    Int J Mol Sci; 2023 Apr 04; 24(7):. PubMed ID: 37047678
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Schmutzler RK, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC.
    J Natl Cancer Inst; 2017 Jul 01; 109(7):. PubMed ID: 28376175
    [Abstract] [Full Text] [Related]

  • 38. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
    Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, Buslov KG, Shilov ES, Togo AV, Bit-Sava EM, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN.
    Fam Cancer; 2007 Jul 01; 6(3):281-6. PubMed ID: 17333477
    [Abstract] [Full Text] [Related]

  • 39. [Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips].
    Fedorova OE, Liubchenko LN, Paiadini IuG, Kazubskaia TP, Amosenko FA, Gar'kavtseva RF, Zasedatelev AS, Nasedkina TV.
    Mol Biol (Mosk); 2007 Jul 01; 41(1):37-42. PubMed ID: 17380889
    [Abstract] [Full Text] [Related]

  • 40. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.
    Am J Hum Genet; 1997 Mar 01; 60(3):505-14. PubMed ID: 9042909
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.